Targeting the signaling pathways associated with necroptosis in order to end, regress or regenerate intervertebral disc degeneration holds great promise in the treatment of disc degeneration. If research achieves this goal, Innovative pharmaceuticals that can modulate the necroptotic pathway may be invented and/or developed and perhaps in the future, new therapeutic modalities may be offered for individuals whose disc degeneration is due to necroptosis. This review aimed to provide a comprehensive overview of intervertebral disc degeneration associated with necroptosis and to contribute to the increasing scientific knowledge in the pharmacomolecular field.